Why China Is A Big Deal For Jaguar Animal Health Inc. (NASDAQ: JAGX)

0

Jaguar Animal Health Inc. (NASDAQ: JAGX) provided an update of its pipeline activity, saying that its drug candidate Neonorm met topline targets in a study that tried the drug in pre-weaned dairy calves. The company is developing the drug as a treatment for dehydration and diarrhea in newborn calves.

Jaguar Animal Health Inc (NASDAQ: JAGX)’s Neonorm is a non-prescription drug that comes in the form of powder and it is mixed with liquid for easy administering.

Trial against placebo

Jaguar collaborated with experts at Cornell University College of Veterinary Medicine to evaluate the efficiency of Neonorm in some 40 newborn bull calves of the Holstein type. In the double-blind, randomized clinical study, the researchers found that calves that received Neonorm demonstrated significant improvement in their symptoms compared to those that received a placebo.

During the study, the participating calves received Neonorm treatment twice a day for a period of two weeks. The calves were observed for 10 more days following their last dose of Neonorm to see how they progressed. The results that the researchers saw impressed them. They noted that calves that received Neonorm had significantly reduced amount of water content in their fecal samples. On top of that, diarrhea reduced in the calves that received Neonorm treatment.

Jaguar’s Neonorm is a preventive medicine that is promising to give farmers the peace of mind in controlling naturally-occurring diarrhea as well as dehydration in calves and piglets.

Trial in piglets

The company said that the outcomes of the trial of Neonorm in calves were consistent with those achieved in a trial of the medicine in piglets in China.

Chinese market is a big deal for Jaguar Animal Health Inc (NASDAQ: JAGX) with its preventive drug Neonorm. Diarrhea is cited as the most common disease affecting newborn pigs, which means that it poses a threat to the global swine market and food security. Given the large numbers of pigs and dairy cattle in China, Jaguar is looking at it as a key market for its Neonorm drug.

The partner that was involved in the trial of Neonorm in China in newborn pigs is likely to be the Jaguar Animal Health Inc. (NASDAQ: JAGX)’s exclusive distributor in the country.

Share.

Leave A Reply